Loading
A phase 1/2 trial of IN10018 in melanoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06708663 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 124 participants planned, started 2025-01-17 and due to reach its primary completion in 2027-12-31. Interventions recorded: HX009+IN10018. Conditions listed: Biliary Tract Cancer, Melanoma. No results are recorded here; the registry entry is the source.